Cytrim 200 Injection contains Cytarabine 200mg, a key chemotherapy drug widely used in the treatment of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and certain lymphomas. As a potent antimetabolite, it works by inhibiting DNA synthesis and targeting rapidly dividing cancer cells, making it a crucial oncology medicine in both adult and pediatric hematology.
This 200mg strength is commonly used in standard-dose chemotherapy cycles, interim dosing schedules, and supportive oncological regimens. Its consistent therapeutic performance and essential role in multi-phase leukemia treatment ensure strong clinical demand across cancer-care setups.
For distributors and oncology suppliers, Cytrim 200 Injection is a steady-moving cancer-care product, frequently required in hematology departments, oncology wards, chemotherapy day-care units, and multispecialty hospitals. Its continuous usage across multiple treatment cycles ensures predictable sales and regular reorder frequency.
Adding Cytrim 200 to your catalogue strengthens your oncology and hematology portfolio, creating opportunities in hospital tenders, institutional supplies, pharmacy distribution, export consignments, and third-party manufacturing services. Its essential role in cancer therapy makes it a high-value and strategically important product for pharmaceutical distributors.